Research 1
Research 1
Research 1
By:
May, 2019
Chapter 1
INTRODUCTION
droplet nuclei. Transmission occurs when a person inhales droplet nuclei containing
tuberculosis bacteria. These droplet nuclei travel via mouth or nasal passages and move into
the upper respiratory tract. Thereafter they reach the bronchi and ultimately to the lungs and
the alveoli, which causes progressive coughing, hemoptysis, chest pain, weight loss, fatigue,
TB is one of the leading causes of death worldwide. Despite the effective treatments,
patients themselves may undermine TB control efforts that may result to multidrug-resistant
(MDR) and extensively drug-resistant (XDR) TB. Drug-resistant TB has been reported since
TB) and more recently extensively drug-resistant tuberculosis (XDR-TB) has been an area of
growing concern and is posing a threat to global efforts of TB control. Poor or high-risk
Persons who are at high risk with being infected with TB includes those who are in
contact with high-risk groups for TB, despite efforts to scale up infection and reduce TB
transmission. Philippines has high prevalence of TB and rising cases of MDR TB and XDR
TB. Understanding the knowledge, attitudes and practices among people in contact with TB
patients is fundamental when it comes to decreasing future TB cases. Therefore, this study
aims to assess the Knowledge, Attitudes, and Practices of people living with TB infected
Statement of Objectives
a. Demographic
b. Socio- economic
a. Causes
c. Diagnosis
Literature Review
Tuberculosis
affects the lungs (pulmonary TB), but can also affect other sites (extrapulmonary TB). The
disease is spread when people who are sick with pulmonary TB expel bacteria into the air, for
example by coughing (WHO, 2018). The risk of progression to active TB and development of
symptoms is about 10% over the course of a lifetime (Frieden 2003), but co-infection with
human immune deficiency virus (HIV) increases this risk to about 10% per year. It is both
About one-quarter of the world's population has latent TB, which means people have
been infected by TB bacteria but are not (yet) ill with the disease and cannot transmit the
disease. People infected with TB bacteria have a 5–15% lifetime risk of falling ill with TB.
However, persons with compromised immune systems, such as people living with HIV,
malnutrition or diabetes, or people who use tobacco, have a much higher risk of falling ill.
When a person develops active TB disease, the symptoms (such as cough, fever, night
sweats, or weight loss) may be mild for many months. This can lead to delays in seeking care,
and results in transmission of the bacteria to others. People with active TB can infect 10–15
other people through close contact over the course of a year. Without proper treatment, 45%
of HIV-negative people with TB on average and nearly all HIV-positive people with TB will
die.
Global impact of TB
TB occurs in every part of the world. In 2017, the largest number of new TB cases
occurred in the South-East Asia and Western Pacific regions, with 62% of new cases,
followed by the African region, with 25% of new cases. In 2017, 87% of new TB cases
occurred in the 30 high TB burden countries. Eight countries accounted for two thirds of the
new TB cases: India, China, Indonesia, Pakistan, Nigeria, Bangladesh and South Africa, the
Philippines.
The Philippines now has the most number of tuberculosis cases in Southeast Asia. But
the Department of Health (DOH, 2018) has clarified that this is only because the country is
using a state-of-the art TB testing machine, which is the most accurate compared to those
Common symptoms of active lung TB are cough with sputum and blood at times,
chest pains, weakness, weight loss, fever and night sweats. Many countries still rely on a
long-used method called sputum smear microscopy to diagnose TB. Trained laboratory
technicians look at sputum samples under a microscope to see if TB bacteria are present.
Microscopy detects only half the number of TB cases and cannot detect drug-resistance.
The use of the rapid test Xpert MTB/RIF® has expanded substantially since 2010,
when WHO first recommended its use. The test simultaneously detects TB and resistance to
rifampicin, the most important TB medicine. Diagnosis can be made within 2 hours and the
test is now recommended by WHO as the initial diagnostic test in all persons with signs and
symptoms of TB.
2016, 4 new diagnostic tests were recommended by WHO – a rapid molecular test to detect
TB at peripheral health centers where Xpert MTB/RIF cannot be used, and 3 tests to detect
Tuberculosis is particularly difficult to diagnose in children and as yet only the Xpert
MTB/RIF assay is generally available to assist with the diagnosis of pediatric TB.
Treatment
with a standard 6 month course of 4 antimicrobial drugs that are provided with information,
supervision and support to the patient by a health worker or trained volunteer. Without such
support, treatment adherence can be difficult and the disease can spread. The vast majority of
TB cases can be cured when medicines are provided and taken properly.
In the Philippines, TB-related facilities have greatly improved over the years. There
are several DOTS (Directly-Observed Treatment Short course) centers helping people with
TB. In 2000, within a span of five years since 1995 when the Philippine government started
to strengthen its TB intervention, the country reported 100% TB-DOTS coverage nationwide.
Between 2000 and 2017, an estimated 54 million lives were saved through TB
Multidrug-Resistant Tuberculosis
Compared with treatment for drug-susceptible TB, treatment for MDR TB is longer, more
expensive, and less effective, and it causes more medication side effects. Resistance to anti-
TB drugs has been detected in all regions of the Philippines; an estimated 8,500 MDR TB
(MDR-TB) (defined as resistance to at least isoniazid and rifampin) in 2013 (3.5% new and
20.5% previously treated TB cases). Likewise, drug resistance surveillance data have shown
that an estimated 480 000 people developed MDR-TB worldwide in 2013, and out of this,
210 000 people died. In 1999, the Green Light Committee (GLC), a partner of the World
(DOTS)-Plus for MDR-TB” programs for patients with MDR-TB. The program emphasizes
the usage of appropriate second-line drugs (SLDs) in low- and middle-income settings. By
the end of 2006, more than 50 DOTS-Plus pilot programs had been launched by GLC, and
drugs to treat MDR-TB, is becoming increasingly important for MDR-TB control globally.
The core components are comprehensive to ensure that all essential elements of the DOTS-
Plus strategy are included. They are the following: sustained political and administrative
testing; appropriate treatment strategies that utilize SLDs under proper management
conditions; and uninterrupted supply of quality-assured anti-TB drugs. (Kibret et al, 2017)
form of TB which is resistant to at least four of the core anti-TB drugs. XDR-TB involves
resistance to the two most powerful anti-TB drugs, isoniazid and rifampicin, also known
MDR-TB and XDR-TB both take substantially longer to treat than ordinary (drug-
susceptible) TB, and require the use of second-line anti-TB drugs, which are more
expensive and have more side-effects than the first-line drugs used for drug-susceptible
TB.
Acquisition of XDR-TB
People may get XDR-TB in one of two ways. It may develop in a patient who is
receiving treatment for active TB, when anti-TB drugs are misused or mismanaged, and is
usually a sign of inadequate clinical care or drug management. It can happen when
patients are not properly supported to complete their full course of treatment; when health-
care providers prescribe the wrong treatment, or the wrong dose, or for too short a period
of time; when the supply of drugs to the clinics dispensing drugs is erratic; or when the
The second way that people can develop XDR-TB is by becoming infected from a
patient who is already ill with the condition. Patients with TB of the lungs can spread the
small number of these germs to become infected. However only a small proportion of
people infected with TB germs develop the disease. A person can be infected by XDR-TB
bacteria but not develop the active disease, just as with drug-susceptible TB.
XDR-TB Transmission
transmission of XDR-TB and any other forms of TB. The spread of TB bacteria depends
on factors such as the number and concentration of infectious people in any one place
together, and the presence of people with a higher risk of being infected (such as those
with HIV/AIDS).
The likelihood of becoming infected increases with the time that a previously
uninfected person spends in the same room as an infectious case. The risk of spread
increases where there is a high concentration of TB bacteria, such as can occur in poorly-
ventilated environments like overcrowded houses, hospitals or prisons. The risk of spread
is reduced if infectious patients receive timely and proper treatment. (WHO, 2019)
communities with a high incidence is by curing it thus, all countries with a TB problem were
to provide standardized short course drug treatment to, at least, all sputum smear positive TB
patients. Due to its prevalence, WHO implemented the directly observed therapy short course
(DOTS) in 1993. DOTS involved treatment with a four drug regimen. These were isoniazid
(INH), Rifampicin (Rif), Pyrazinamide (PZA) and Ethambutol (EMB) for 6-9 months. One of
the major achievement of DOTS since its implementation has been its apparent ability to
limit the development and spread of acquired drug resistance by improving adherence by
requiring health workers, community volunteers or family members to observe and record
patients taking each dose (Chaundry et.al 2012). However, outcomes are poor when patients
who are infected with Mycobacterium tuberculosis resistant to isoniazid and rifampicin
(multidrug resistant tuberculosis) are treated with the standard regimen. Reserve or second
national programs. This approach is known as DOTS-plus. In DOTS-plus, second line anti-
tuberculosis drugs which are more toxic and expensive, and less effective than first line
drugs, are used. Total duration of treatment is 18-24 months. (Tupasi, et.al). According
Quelapio, et.al, DOTS is effective for new smear-positive pulmonary TB. For re-treatment
cases however, the DOTS-Plus strategy appears essential due to the high rate of treatment
package of the Philippine Health Insurance Corporation (Phil Health) for pediatric and adult
tuberculosis. The outpatient TB-DOTS Package is designed only for new cases of pulmonary
and extra-pulmonary TB in children and adults and does not cover cases of patients who
returned for treatment after interruption for two or more months. (Yao, 2012)
A Central team at the National Center for The tuberculosis profile of the Philippines:
A Central team at the National Center for The tuberculosis profile of the Philippines manages
the National TB Control Program (NTP), 2003–2015. Disease Prevention and Control of the
Department of Health. This team develops policies and plans and provides technical guidance
to regional and provincial/ city-level NTP management teams, overseeing the implementation
of the program at the municipal and barangay levels based on NTP policies and standards.
Under NTP, TB control services are provided mainly through public primary health care
facilities (also called DOTS facilities) operated by local government units in a devolved set-
up. The Philippines has achieved improvements in case detection and exceeded the target for
The country aims to further improve access to diagnostic and treatment services,
especially for highly vulnerable groups, while sustaining high cure and treatment success
rates particularly among smear-positive PTB cases. Efforts will be directed at improving
examinations for patients under treatment as well as the factors that promote treatment
default and improving the referral system to reduce transfer-outs. Factors that contribute to
TB mortality such as diagnostic and treatment delay and co-morbidities need to be addressed
as well. Finally, the TB information system will be strengthened to improve its usefulness for
surveillance, planning and decision making. With the current trend of NTP performance, it is
predicted that the country will achieve" At least 40 million people with TB reached with care
in the period 2018–2022, including 3.5 million children and 1.5 million people with drug-
resistant TB At least 30 million people reached with TB prevention services in the period
(WHO, 2018)
greater than the general population (Tudor, C et.al 2014). Their exposure to TB will increase
multi-drug resistant TB (Rafiza,S. et al 2011). Nosocomial exposure was attributed to the risk
of TB disease among healthcare workers with a range of 25 to 5,361 per 100,000 yearly, as
(Joshi, R et al 2013).
Health care workers should receive high quality periodic TB education and training
needs, and educational backgrounds. Special attention should be given to training non-
clinical, auxiliary and support staff to improve their KAP and prepare them to safely work in
Conceptual Framework
Tuberculosis (TB) remains a major challenge to global health. Health care workers
have an increased risk of acquiring TB compared with the general population, as they are
Chapter 2
RESEARCH METHODOLOGY
Research Design
assessing the Knowledge, Attitudes, and Practices of Health-related and Non-Health Related
This study will make use of questionnaire that consists of 2 parts. First part involves
demographic profile of respondents (age, sex, marital status, educational status, occupation);
second part involves questions about curability, treatment duration, prevalence, MDR TB,
and the TB control program provisions for free anti-TB drugs and free diagnostic tests. The
Total enumeration will be used to gather sample size. The respondents will be health-
Research instrumentation
A. Questionnaires
The questionnaire will consist of four sections. The first section will
educational status, marital status, and occupation). The second section will
contain items to assess their practices towards TB. This encompasses the
practices on prevention further spread and progression of TB. The third section
consists of the attitudes of the respondents towards TB. This encompasses the
The fourth section will contain items to assess their knowledge on tuberculosis.
prevention of TB.
B. Interview
Interviews shall be carried out to both health-related workers and non-health related
workers to determine the factors that affect their knowledge, attitudes and practices.
C. Observation
practices that may affect certain attitudes and practices they are routinely do.
Analytical Framework
The data collected regarding knowledge about TB, treatment duration, MDR TB,
and the TB control program provisions for free anti-TB drugs and free diagnostic tests will
be
analyzed using SPSS version 20 (IBM Corp., Armonk, NY, USA). Data regarding the basic
status, occupational status, and marital status. The data collected under the profile of
attitudes, and practices will be analyzed using mean and standard deviation. ANOVA will
association between the knowledge of respondents on tuberculosis with that of attitudes and
patients?
Yes
No
Health center
Quack doctors
Hospital
Nowhere/ nobody
Do not know
4-6 days
7 or more
Do not know
1. What was your initial reaction when you found out that your family member is
Sad
Disgusted
Frightened
a) Yes b) No
Friends
Family members
Newspaper/pamphlets
Radio
Television
Medical staff
Bacteria
Virus
Over fatigue
Unhealthy lifestyle
Cigarette smoking
Inherited
Urine
Sputum
Cerebrospinal fluid
Sexual transmission
Direct contact
Ingestion
Lungs
Bones
Heart
Kidney
7. Means for TB diagnosis
Using X-ray
Sputum Test
Do not know
3 months
6 months
12 months
15 months
10. Do you know that Philippines has the highest cases of TB in Southeast Asia?
a) Yes b) No
6 months
12 months
18 months
24 months
13. Do you know XDR TB (Extensively Drug Resistant TB)? a) Yes b) No
15. Do you know that National TB Control Program (NTP) is providing free of cost
16. Do you know that TB organism Mycobacterium tuberculosis) can be detected via PCR
a) Yes b) No
ANNEX B
INFORMED CONSENT
Benefit: The respondents can gain more knowledge, evaluate and assess the attitudes and
practices that are needed to be improved.
I confirm that I have read and understood the information about the research as stated
above.
I understand that my participation is voluntary and that I am free to withdraw from the
research at any time, without having to give a reason and without any consequences.
I understand that any information will remain confidential and no information that
identifies me will be made publicly available.
I agree to take part in the above study.